Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Private Payers’ ESA Policies Will Differ From Medicare NCD – Amgen

Executive Summary

Commercial insurers are unlikely to follow CMS' recent national coverage determination on erythropoiesis-stimulating agents for non-renal disease uses, Amgen is predicting

You may also be interested in...



ASCO/ASH Guideline Preserves Higher ESA Dosing Options For Cancer Patients

Despite the emergence of safety concerns related to use of erythropoiesis-stimulating agents in recent years, the American Society of Hematology and the American Society of Clinical Oncology are essentially providing the same dosing recommendations in their latest guideline for treatment of chemotherapy-induced anemia as in the previous version from five years ago

ASCO/ASH Guideline Preserves Higher ESA Dosing Options For Cancer Patients

Despite the emergence of safety concerns related to use of erythropoiesis-stimulating agents in recent years, the American Society of Hematology and the American Society of Clinical Oncology are essentially providing the same dosing recommendations in their latest guideline for treatment of chemotherapy-induced anemia as in the previous version from five years ago

Medicare ESA Policy May Find Support In FDA Letter But J&J Sees Differently

Key Democratic legislators are spotlighting an FDA letter on erythropoiesis-stimulating agents as indicating agreement between FDA and Medicare policies, but some stakeholders interpret it as pointing out differences between the agencies

Related Content

UsernamePublicRestriction

Register

LL1131867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel